Presentation and management of a stage Ia lung cancer patient with a paraneoplastic factor VIII inhibitor.
Acquired inhibitors to clotting factors most commonly involve factor VIII and are associated with autoimmune disease. Factor VIII inhibitors can cause severe spontaneous and iatrogenic bleeding that is difficult to manage. Factor VIII inhibitors are rarely associated with solid tumors and only three cases of adenocarcinoma of the lung have been reported. This report describes the multidisciplinary management of a factor VIII inhibitor-producing stage Ia lung adenocarcinoma that ultimately resulted in complete resectability.
Laselle
Brooks T
BT
Division of Hematology/Oncology, Northwestern Memorial Hospital, Chicago, Illinois, USA.
Boggio
Lisa N
LN
Blum
Matthew G
MG
D000230:Adenocarcinoma / Q000097:blood* / Q000150:complications / Q000188:drug therapy / Q000276:immunology / Q000473:pathology / Q000601:surgery; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001323:Autoantibodies / Q000276:immunology*; D001327:Autoimmune Diseases / Q000209:etiology* / Q000276:immunology; D001779:Blood Coagulation Factors / Q000627:therapeutic use*; D016063:Blood Loss, Surgical / Q000517:prevention & control*; D016190:Carboplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000627:therapeutic use; D003924:Diabetes Mellitus, Type 2 / Q000150:complications; D005169:Factor VIII / Q000037:antagonists & inhibitors / Q000276:immunology*; D006470:Hemorrhage / Q000209:etiology* / Q000276:immunology; D006801:Humans; D006943:Hyperglycemia / Q000139:chemically induced / Q000209:etiology; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008175:Lung Neoplasms / Q000097:blood* / Q000150:complications / Q000188:drug therapy / Q000276:immunology / Q000473:pathology / Q000601:surgery; D008297:Male; D009367:Neoplasm Staging; D017239:Paclitaxel / Q000008:administration & dosage; D010257:Paraneoplastic Syndromes / Q000209:etiology* / Q000276:immunology; D010314:Partial Thromboplastin Time; D011013:Pneumonectomy; D011241:Prednisone / Q000009:adverse effects / Q000627:therapeutic use
D001323:Autoantibodies; D001779:Blood Coagulation Factors; D016756:Immunoglobulins, Intravenous; D007166:Immunosuppressive Agents; D003520:Cyclophosphamide; D005169:Factor VIII; D016190:Carboplatin; C065655:anti-inhibitor coagulant complex; D017239:Paclitaxel; D011241:Prednisone